The approval covers Jemperli's use in combination with chemotherapy ... UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. A panel of leaders at the PMCPA, pharma’s ...

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...

PHILADELPHIA, February 17, 2025--PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY The report provides insights into GSK's tech activities, including ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

Teva Pharmaceutical Industries Ltd. ADR-1.53% $19.99B ...